250
Participants
Start Date
June 1, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
September 30, 2026
ORIC-944
Oral, once daily, continuous
Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
Oral, 1000 mg once daily, continuous
Apalutamide (Erleada™) 60 mg or 240 mg tablets
Oral, 240 mg once daily, continuous
Darolutamide (Nubeqa®) 300 mg tablets
Oral, 600 mg twice daily, continuous
Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Oral, 160 mg once daily, continuous
RECRUITING
Memorial Sloane Kettering Cancer Center, New York
RECRUITING
Keystone Urology Specialists, Lancaster
NOT_YET_RECRUITING
MidLantic Urology, Bala-Cynwyd
RECRUITING
Maryland Oncology Hematology, Silver Spring
RECRUITING
Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore
RECRUITING
Virginia Oncology Associates, Fairfax
NOT_YET_RECRUITING
Virginia Cancer Specialists, Norfolk
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
South Florida Oncology and Hematology, Plantation
RECRUITING
First Urology, Jeffersonville
RECRUITING
Karmanos, Detroit
NOT_YET_RECRUITING
University of Wisconsin Carbone Cancer Center, Madison
RECRUITING
Minnesota Oncology Hematology, Minneapolis
RECRUITING
Illinois Cancer Specialists, Arlington Heights
RECRUITING
Comprehensive Urologic Care, Lake Barrington
RECRUITING
Amarillo Urology Research, Amarillo
RECRUITING
Urology Clinics of North Texas, Dallas
RECRUITING
Rocky Mountain Cancer Center, Colorado Springs
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
University of Washington, Fred Hutchinson Cancer Center, Seattle
RECRUITING
Sydney Adventist Health, Wahroonga
RECRUITING
Bendigo Health, Bendigo
NOT_YET_RECRUITING
Peninsula Health, Frankston
RECRUITING
NEXT Oncology, Barcelona
RECRUITING
Vall d'Hebron Institute of Oncology, Barcelona
RECRUITING
NEXT Oncology, Madrid
RECRUITING
Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
ORIC Pharmaceuticals
INDUSTRY